Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo | Zendy

Xiaokai Ding | Zendy; Amanda C. Sharko | Zendy; Martina S.J. McDermott | Zendy; Gary P. Schools | Zendy; Alexander A. Chumanevich | Zendy; Hao Ji | Zendy; Jing Li | Zendy; Li Zhang | Zendy; Zachary T. Mack | Zendy; Vitali Sikirzhytski | Zendy; Michael Shtutman | Zendy; Laura Ivers | Zendy; Norma O’Donovan | Zendy; John Crown | Zendy; Balázs Győrffy | Zendy; Mengqian Chen | Zendy; Igor B. Roninson | Zendy; Eugenia V. Broude | Zendy

Open Access

Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo

Author(s) -

Xiaokai Ding,

Amanda C. Sharko,

Martina S.J. McDermott,

Gary P. Schools,

Alexander A. Chumanevich,

Hao Ji,

Jing Li,

Li Zhang,

Zachary T. Mack,

Vitali Sikirzhytski,

Michael Shtutman,

Laura Ivers,

Norma O’Donovan,

John Crown,

Balázs Győrffy,

Mengqian Chen,

Igor B. Roninson,

Eugenia V. Broude

Publication year - 2022

Publication title -

proceedings of the national academy of sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.011

H-Index - 771

eISSN - 1091-6490

pISSN - 0027-8424

DOI - 10.1073/pnas.2201073119

Subject(s) - lapatinib , cancer research , trastuzumab , pi3k/akt/mtor pathway , protein kinase b , reprogramming , tyrosine kinase , medicine , kinase , erbb , pharmacology , cancer , signal transduction , biology , breast cancer , cell , microbiology and biotechnology , biochemistry

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research